 |
|
|
| |
SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF OBETICHOLIC ACID IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS OR CIRRHOSIS
|
| |
| |
AASLD 2019 Nov 8-12 Boston
Dr. Naim Alkhouri1, Fred Poordad2, Eric J. Lawitz2, Dr. Jason Boyd3 and Dr. Jeffrey Edwards3, (1)Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA, (2)Texas Liver Institute, University of Texas Health Science Center, (3)Intercept Pharmaceuticals, Inc.
|
| |
|
|
|
|
|
